Pharmaceutical

LSPedia AND OMNICELL COLLABORATE IN AN EFFORT TO ADVANCE PHARMACY SUPPLY CHAIN COMPLIANCE AND INNOVATION FOR HOSPITALS AND HEALTH SYSTEMS

FARMINGTON HILLS, Mich., Dec. 4, 2024 /PRNewswire/ -- LSPedia, a leading provider of traceability and compliance solutions for the pharmaceutical…

3 weeks ago

BioFuse Medical Technologies Announces New CEO and Strategic Appointments to Advisory Team

TAMPA, FL / ACCESSWIRE / December 4, 2024 / BioFuse Medical Technologies proudly announces the appointment of Rick Earley as…

3 weeks ago

Ovation Science Licensee Launches Innovative Transdermal Cannabis Products in Pennsylvania

VANCOUVER, BC / ACCESSWIRE / December 4, 2024 / (CSE:OVAT)(OTC PINK:OVATF) - Ovation Science Inc. ("Ovation" or the "Company"), with…

3 weeks ago

180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a…

3 weeks ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~ SAN DIEGO, CA / ACCESSWIRE / December…

3 weeks ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Next PMDA Consultation after Review of CardiAMP HF Trial DataSUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA],…

3 weeks ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved…

3 weeks ago

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use…

3 weeks ago

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

WARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company…

3 weeks ago

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

Pivotal Phase 3 4WARD clinical trial is evaluating use of oral mavorixafor as monotherapy and in combination with injectable G-CSFBOSTON,…

3 weeks ago